Antiplatelet drugs in cardiological practice: Established strategies and new developments

References

• AngiolilloDJFernandez-OrtizABernardoEPlatelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatmentDiabetes2005542430516046311
   PubMed Web of Science ®Google Scholar
• AngiolilloDJShoemakerSBDesaiBRandomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) studyCirculation20071157081617261652
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ CollaborationCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ20023247329718611786451
   PubMed Web of Science ®Google Scholar
• AwtryEHLoscalzoJAspirinCirculation200010112061810715270
   PubMed Web of Science ®Google Scholar
• BalsanoFVioliFCimminielloCTiclopidine in unstable anginaCirculation199082228232242554
   PubMed Web of Science ®Google Scholar
• BelhassenLPelleGDubois-RandeJLImproved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirinJ Am Coll Cardiol200341119820412679222
   PubMed Web of Science ®Google Scholar
• BertrandMERupprechtHJUrbanPDouble-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS)Circulation2000102624910931801
   PubMed Web of Science ®Google Scholar
• BhattDLFoxKAHackeWClopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsN Engl J Med200635417061716531616
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering CommitteeA randomised blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering CommitteeLancet1996348∧9038132939
   Google Scholar
• CattaneoMPlatelet P2 receptors: old and new targets for antithrombotic drugsExpert Rev Cardiovasc Ther20075455517187456
   PubMedGoogle Scholar
• ChewDPBhattDLSappSIncreased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trialsCirculation2001103201611208677
   PubMed Web of Science ®Google Scholar
• CipolloneFPatrignaniPGrecoADifferential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable anginaCirculation1997961109169286937
   PubMed Web of Science ®Google Scholar
• CoccheriSApproaches to prevention of cardiovascular complications and events in diabetes mellitusDrugs200767997102617488145
   PubMed Web of Science ®Google Scholar
• CravenLLExperiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosisMiss Valley Med J195375384413013156
   PubMedGoogle Scholar
• DanielJLDangelmaierCJinJMolecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human plateletsJ Biol Chem1998273202499442039
   PubMed Web of Science ®Google Scholar
• De SchryverELAlgraAvan GijnJDipyridamole for preventing stroke and other vascular events in patients with vascular diseaseCochrane Database Syst Rev20073CD00182017636684
   PubMedGoogle Scholar
• DienerHCBogousslavskyJBrassLMAspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trialLancet20043649431331715276392
   PubMed Web of Science ®Google Scholar
• DorsamRTKunapuliSPCentral role of the P2Y12 receptor in platelet activationJ Clin Invest2004113340514755328
   PubMed Web of Science ®Google Scholar
• DubeCRostomALewinGThe use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task ForceAnn Intern Med20071463657517339622
   PubMed Web of Science ®Google Scholar
• EisensteinELAnstromKJKongDFClopidogrel use and long-term clinical outcomes after drug-eluting stent implantationJAMA20072971596817148711
   PubMed Web of Science ®Google Scholar
• EshaghianSKaulSAminSRole of clopidogrel in managing atherothrombotic cardiovascular diseaseAnn Intern Med20071464344117371888
   PubMed Web of Science ®Google Scholar
• EvangelistaVManariniSDi SantoADe novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirinCirc Res200698593516484611
   PubMed Web of Science ®Google Scholar
• FusterVBadimonLBadimonJJThe pathogenesis of coronary artery disease and the acute coronary syndromes (2)N Engl J Med1992326310181728735
   PubMed Web of Science ®Google Scholar
• GawazMLangerHMayAEPlatelets in inflammation and atherogenesisJ Clin Invest200511533788416322783
   PubMed Web of Science ®Google Scholar
• GreenbaumABGrinesCLBittlJAInitial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trialAm Heart J200615168916504633
   PubMed Web of Science ®Google Scholar
• HalkesPHvan GijnJKappelleLJAspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trialLancet2006367952316657316714187
   PubMed Web of Science ®Google Scholar
• HuoYSchoberAForlowSBCirculating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein ENat Med2003961712483207
   PubMed Web of Science ®Google Scholar
• ISIS-2 Collaborative GroupRandomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative GroupLancet198828607349602899772
   PubMedGoogle Scholar
• JacksonSPNesbittWSKulkarniSSignaling events underlying thrombus formationJ Thromb Haemost2003116021212871297
   PubMed Web of Science ®Google Scholar
• JinJDanielJLKunapuliSPMolecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in plateletsJ Biol Chem1998273203049442040
   PubMed Web of Science ®Google Scholar
• KleinschnitzCPozgajovaMPhamMTargeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleedingCirculation200711523233017438148
   PubMed Web of Science ®Google Scholar
• KongDFCaliffRMMillerDPClinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart diseaseCirculation1998982829359860783
   PubMed Web of Science ®Google Scholar
• LegerAJCovicLKuliopulosAProtease-activated receptors in cardiovascular diseasesCirculation20061141070716952995
   PubMed Web of Science ®Google Scholar
• LollPJPicotDGaravitoRMThe structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthaseNat Struct Biol19952637437552725
   PubMedGoogle Scholar
• MansonJEStampferMJColditzGAA prospective study of aspirin use and primary prevention of cardiovascular disease in womenJAMA199126652172061978
   PubMed Web of Science ®Google Scholar
• MareeAOFitzgeraldDJVariable platelet response to aspirin and clopidogrel in atherothrombotic diseaseCirculation2007115219620717452618
   PubMed Web of Science ®Google Scholar
• MauriLHsiehWHMassaroJMStent thrombosis in randomized clinical trials of drug-eluting stentsN Engl J Med20073561020917296821
   PubMed Web of Science ®Google Scholar
• Neri SerneriGGCoccheriSMarubiniEPicotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID studyEur Heart J20042518455215474700
   PubMed Web of Science ®Google Scholar
• NieswandtBWatsonSPPlatelet-collagen interaction: is GPVI the central receptor?Blood20031024496112649139
   PubMed Web of Science ®Google Scholar
• NymanILarssonHWallentinLPrevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. The Research Group on Instability in Coronary Artery Disease in Southeast SwedenLancet199234088184975011354274
   PubMed Web of Science ®Google Scholar
• PatrignaniPFilabozziPPatronoCSelective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjectsJ Clin Invest1982691366727045161
   PubMed Web of Science ®Google Scholar
• PatronoCCollerBFitzGeraldGAPlatelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest20041263 Suppl234S264S15383474
   PubMed Web of Science ®Google Scholar
• PatronoCRoccaBDrug insight: aspirin resistance – fact or fashion?Nat Clin Pract Cardiovasc Med20074425017180149
   PubMedGoogle Scholar
• PetoRGrayRCollinsRRandomised trial of prophylactic daily aspirin in British male doctorsBMJ (Clin Res Ed)1988296661831316
   PubMed Web of Science ®Google Scholar
• Physician’s Health Study GroupPhysician’s health study: aspirin and primary prevention of coronary heart diseaseN Engl J Med1989321182582594041
   PubMedGoogle Scholar
• PinedoHMVerheulHMD’AmatoRJInvolvement of platelets in tumour angiogenesis?Lancet19983529142177579848370
   PubMed Web of Science ®Google Scholar
• RidkerPMCookNRLeeIMA randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in womenN Engl J Med2005352129330415753114
   PubMed Web of Science ®Google Scholar
• RuggeriZMVon Willebrand factor, platelets and endothelial cell interactionsJ Thromb Haemost2003113354212871266
   PubMed Web of Science ®Google Scholar
• SchaperWDipyridamole, an underestimated vascular protective drugCardiovasc Drugs Ther2005193576316382298
   PubMed Web of Science ®Google Scholar
• ShankarHKahnerBKunapuliSPG-protein dependent platelet signaling--perspectives for therapyCurr Drug Targets2006712536317073586
   PubMed Web of Science ®Google Scholar
• ShattilSJFunction and regulation of the beta 3 integrins in hemostasis and vascular biologyThromb Haemost199574149558578448
   PubMed Web of Science ®Google Scholar
• SiessWMolecular mechanisms of platelet activationPhysiol Rev198969581782536184
   PubMed Web of Science ®Google Scholar
• StoneGWEllisSGColomboAOffsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantationCirculation20071152842717515458
   PubMed Web of Science ®Google Scholar
• Thrombosis Prevention Trial Study GroupThrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research FrameworkLancet19983519098233419457092
   PubMed Web of Science ®Google Scholar
• VilahurGCasaniLBadimonLA thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosisThromb Haemost200798662917849057
   PubMed Web of Science ®Google Scholar
• von BeckerathNKastratiAWieczorekAA double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 daysEur Heart J20072818141917272357
   PubMed Web of Science ®Google Scholar
• WallentinLCAspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast SwedenJ Am Coll Cardiol1991181587931960301
   PubMed Web of Science ®Google Scholar
• WangTHBhattDLTopolEJAspirin and clopidogrel resistance: an emerging clinical entityEur Heart J2006276475416364973
   PubMed Web of Science ®Google Scholar
• WeissHJAledortLMKochwaSThe effect of salicylates on the hemostatic properties of platelets in manJ Clin Invest1968472169805675432
   PubMed Web of Science ®Google Scholar
• WiviottSDAntmanEMWintersKJRandomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trialCirculation200511133667315967851
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med200735720011517982182
   PubMed Web of Science ®Google Scholar
• WorthNFBerryCLThomasACS18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbitsAtherosclerosis2005183657315950232
   PubMed Web of Science ®Google Scholar